Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

JIROborn

Financiado

Cerrado

Unravelling the role of Pneumocystis jirovecii in utero infection in early and l...

Unravelling the role of Pneumocystis jirovecii in utero infection in early and late pulmonary diseases of very preterm infants. Very preterm birth represent about 1% of livebirths in Europe each year and is associated with 58% of neonatal deaths and substantial lifetime health problems. Pneumocystis jirovecii is an ubiquitous microfungus commonly known for... ver más

31/05/2026

181K€

Presupuesto del proyecto: 181K€

Líder del proyecto

UNIVERSIDAD DE SEVILLA No se ha especificado una descripción o un objeto social para esta compañía.

Total investigadores 3671

Fecha límite participación Sin fecha límite de participación.

Financiación concedida El organismo HORIZON EUROPE notifico la concesión del proyecto el día 2024-04-05

HORIZON-MSCA-2023-PF-01-01: MSCA Postdoctoral Fellowships 2023 ExpectedOutcome:Project results are expected to contribute to the following outcomes:

I+D

Cerrada hace 1 año

0% 100%

Características del participante

Este proyecto no cuenta con búsquedas de partenariado abiertas en este momento.

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

1 Participantes

181.15K€ | Lider

Proyectos interesantes

SAF2009-11632

Medical Technol...

Biotechnology

456K€ Cerrado

Trained_Lung

Medical Technol...

Environmental S...

Cerrado

RespiriCO

Medical Technol...

Public Health

192K€ Cerrado

PID2021-127755OB-I00

Medical Technol...

Immunology

260K€ Cerrado

CHILD-INNOVAC

Medical Technol...

Vaccinology

7M€ Cerrado

FLU-MACROPHAGE

Medical Technol...

Infectious Dise...

180K€ Cerrado

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Duración del proyecto: 25 meses Fecha Inicio: 2024-04-05
Fecha Fin: 2026-05-31

Líder del proyecto

UNIVERSIDAD DE SEVILLA No se ha especificado una descripción o un objeto social para esta compañía.

Total investigadores 3671

Presupuesto del proyecto 181K€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto Very preterm birth represent about 1% of livebirths in Europe each year and is associated with 58% of neonatal deaths and substantial lifetime health problems. Pneumocystis jirovecii is an ubiquitous microfungus commonly known for causing a severe interstitial pneumonia in immunosuppressed subjects. However, this could be the tip of the iceberg and compelling new evidences suggest that this infection may be pathogenic to certain groups of infants. In utero transmission of P. jirovecii in humans has been recently proven. The fungus has been found in the lungs of 14-25% preterm newborns, associated with an increased risk of respiratory distress syndrome (RDS) and bronchopulmonary dysplasia. The ability of P. jirovecii to change the pulmonary environment has been demonstrated in other contexts, inducing a modification of the host immune response, pulmonary dysbiosis and thickening of pulmonary alveoli. Genetic polymorphisms have also been independently implicated in both an increased risk of preterm bi or neonatal RDS and a susceptibility to P. jirovecii. Hence, JIROborn aims to address the impact of P. jirovecii in utero infection on the preterm infants’ lungs alteration and on the development of subsequent early or late diseases, constructing a predictive model for monitoring preterm infants’ related pulmonary complications. JIROborn is a nested case control study using a prospective cohort of 596 infected and uninfected preterm infants and their mothers. First, the clinical impact of P. jirovecii infection will be evaluated for early and later lung complications. Then, biological effects of the infection will be studied focusing on the immune parameters, the microbiota and on surfactant and mucus production. Genetic and epigenetic susceptibilities to P. jirovecii colonization and/or to the development of pulmonary diseases will be evaluated. Finally, all data will be analysed to build a predictive model for the monitoring of preterm infants’ pulmonary complications.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores